Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Documenti analoghi

• Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the POETYK PSO‐4 study
  di: Yayoi Tada, et al.
  Pubblicazione: (2024)
• Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO ‐1, PSO ‐4, and LTE trials
  di: Akimichi Morita, et al.
  Pubblicazione: (2025)
• Real‐world evidence for comprehensive evaluation of guselkumab in the treatment of psoriasis
  di: Diamant Thaçi
  Pubblicazione: (2025)
• Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
  di: Bruce Strober, et al.
  Pubblicazione: (2024)
• Optical coherence tomography‐based imaging biomarkers for disease activity monitoring in plaque psoriasis
  di: L. Ha‐Wissel, et al.
  Pubblicazione: (2024)